Thyrocare Technologies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Thyrocare Technologies şirketinin toplam hissedar öz sermayesi ₹4.9B ve toplam borcu ₹1.2M olup, bu da borç-öz sermaye oranını 0.02% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹6.0B ve ₹1.1B dir. Thyrocare Technologies 'in FAVÖK'ü ₹1.1B faiz karşılama oranı 86.7 dur. Şirketin ₹1.4B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

0.02%

Borç/özkaynak oranı

₹1.20m

Borç

Faiz karşılama oranı	86.7x
Nakit	₹1.38b
Eşitlik	₹4.89b
Toplam yükümlülükler	₹1.08b
Toplam varlıklar	₹5.97b

Son finansal sağlık güncellemeleri

Here's Why Thyrocare Technologies (NSE:THYROCARE) Can Manage Its Debt Responsibly

Dec 08

Recent updates

Statutory Profit Doesn't Reflect How Good Thyrocare Technologies' (NSE:THYROCARE) Earnings Are

Oct 31

Thyrocare Technologies Limited (NSE:THYROCARE) Looks Just Right With A 26% Price Jump

Aug 01

Thyrocare Technologies Limited (NSE:THYROCARE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Jul 26

A Look At The Fair Value Of Thyrocare Technologies Limited (NSE:THYROCARE)

Jun 12

Getting In Cheap On Thyrocare Technologies Limited (NSE:THYROCARE) Might Be Difficult

Feb 29

Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Feb 04

Here's Why Thyrocare Technologies (NSE:THYROCARE) Can Manage Its Debt Responsibly

Dec 08

Why Thyrocare Technologies' (NSE:THYROCARE) Shaky Earnings Are Just The Beginning Of Its Problems

Nov 08

Thyrocare Technologies (NSE:THYROCARE) Knows How To Allocate Capital Effectively

Mar 23

Thyrocare Technologies Limited (NSE:THYROCARE) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Mar 02

Investors In Thyrocare Technologies Limited (NSE:THYROCARE) Should Consider This, First

Feb 01

Investors Who Bought Thyrocare Technologies (NSE:THYROCARE) Shares A Year Ago Are Now Up 81%

Jan 12

The Chairman & MD of Thyrocare Technologies Limited (NSE:THYROCARE), Velumani Arokiaswamy, Just Bought A Few More Shares

Dec 24

Under The Bonnet, Thyrocare Technologies' (NSE:THYROCARE) Returns Look Impressive

Dec 17

Thyrocare Technologies Limited's (NSE:THYROCARE) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Nov 30

Analyst Forecasts For Thyrocare Technologies Limited (NSE:THYROCARE) Are Surging Higher

Nov 02

Earnings Update: Thyrocare Technologies Limited (NSE:THYROCARE) Just Reported And Analysts Are Boosting Their Estimates

Nov 01

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: THYROCARE 'nin kısa vadeli varlıkları ( ₹2.4B ) kısa vadeli yükümlülüklerini ( ₹948.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: THYROCARE şirketinin kısa vadeli varlıkları ( ₹2.4B ) uzun vadeli yükümlülüklerini ( ₹135.7M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: THYROCARE şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: THYROCARE 'nin borç/öz sermaye oranı son 5 yılda 0.7% seviyesinden 0.02% seviyesine düştü.

Borç Kapsamı: THYROCARE 'nin borcu işletme nakit akışı ( 156050% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: THYROCARE 'in borcuna ilişkin faiz ödemeleri EBIT ( 86.7 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Thyrocare Technologies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why Thyrocare Technologies (NSE:THYROCARE) Can Manage Its Debt Responsibly

Recent updates

MD, CEO & Chairman recently bought ₹1.1m worth of stock

Statutory Profit Doesn't Reflect How Good Thyrocare Technologies' (NSE:THYROCARE) Earnings Are

Price target increased by 9.1% to ₹903

Second quarter 2025 earnings released: EPS: ₹4.99 (vs ₹3.84 in 2Q 2024)

High number of new directors

Thyrocare Technologies Limited to Report Q2, 2025 Results on Oct 23, 2024

Now 23% overvalued after recent price rise

Price target increased by 8.5% to ₹828

Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million.

Thyrocare Technologies Limited Announces Cessation of Mr. Neetin Shivajirao Desai as Independent Director as Well as Member of the Respective Committee(s) of the Board

Now 20% overvalued after recent price rise

Thyrocare Technologies Limited Approves Dividend for the Financial Year 2023-24

Thyrocare Technologies Limited Announces Cessation of Gopalkrishna Shivaram Hegde as Independent Director and as Member / Chairman of the Respective Committee

Now 20% overvalued after recent price rise

Upcoming dividend of ₹18.00 per share

Thyrocare Technologies Limited, Annual General Meeting, Aug 23, 2024

Thyrocare Technologies Limited (NSE:THYROCARE) Looks Just Right With A 26% Price Jump

Investor sentiment improves as stock rises 20%

Thyrocare Technologies Limited (BSE:539871) acquired Diagnostic and pathological services business of Polo Labs Private Limited for INR 42.6 million.

Thyrocare Technologies Limited (NSE:THYROCARE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Now 23% overvalued after recent price rise

First quarter 2025 earnings released: EPS: ₹4.52 (vs ₹3.26 in 1Q 2024)

Thyrocare Technologies Limited to Report Q1, 2025 Results on Jul 23, 2024

Now 23% overvalued after recent price rise

A Look At The Fair Value Of Thyrocare Technologies Limited (NSE:THYROCARE)

New major risk - Revenue and earnings growth

Thyrocare Technologies Limited Proposes Final Dividend for the Financial Year 2023-24

Thyrocare Technologies Limited to Report Q4, 2024 Results on May 14, 2024

Getting In Cheap On Thyrocare Technologies Limited (NSE:THYROCARE) Might Be Difficult

Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Think Health Diagnostic Private Limited.

Revenue Miss: Thyrocare Technologies Limited Fell 10.0% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Third quarter 2024 earnings released: EPS: ₹2.78 (vs ₹1.89 in 3Q 2023)

Thyrocare Technologies Limited to Report Q3, 2024 Results on Feb 01, 2024

Price target increased by 7.3% to ₹695

Here's Why Thyrocare Technologies (NSE:THYROCARE) Can Manage Its Debt Responsibly

Why Thyrocare Technologies' (NSE:THYROCARE) Shaky Earnings Are Just The Beginning Of Its Problems

Second quarter 2024 earnings released: EPS: ₹3.84 (vs ₹3.80 in 2Q 2023)

Thyrocare Technologies Limited to Report Q2, 2024 Results on Oct 31, 2023

MD, CEO & Chairman recently bought ₹4.3m worth of stock

Thyrocare Technologies Limited Appoints Alok Kumar Jagnani as Chief Financial Officer

High number of new directors

Thyrocare Technologies Limited to Report Q1, 2024 Results on Aug 01, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited Accepts Resignation of Sachin Salvi as Chief Financial Officer

Price target decreased by 7.0% to ₹730

Full year 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q4, 2023 Results on May 23, 2023

Thyrocare Technologies Limited Announces Resignation of Vishwas Kulkarni as an Independent Director

Upcoming dividend of ₹18.00 per share at 3.1% yield

MD, CEO & Director recently bought ₹10m worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q3, 2023 Results on Feb 03, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited (BSE:539871) agreed to acquire 51% stake in Pulse Hitech Health Services (Ghatkopar) LLP for INR 25.5 million.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q2, 2023 Results on Nov 11, 2022

MD, CEO & Director recently bought ₹16m worth of stock

Thyrocare Technologies Limited Announces Payment of Interim Dividend for the Financial Year 2021-2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited, Annual General Meeting, Aug 03, 2022

Price target decreased to ₹1,073

Thyrocare Technologies Limited Joins Rahul Guha as Managing Director

Thyrocare Technologies Limited Declares Interim Dividend for the Financial Year 2021-22

Full year 2022 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q4, 2022 Results on Apr 29, 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Thyrocare Technologies Limited Announces Appointment of Rahul Guha as Managing Director

Thyrocare Technologies Limited Appoints Sachin Salvi as Chief Financial Officer

First quarter 2022 earnings released: EPS ₹10.51 (vs ₹0.04 in 1Q 2021)

First quarter 2022 earnings released: EPS ₹10.51 (vs ₹0.04 in 1Q 2021)

Price target increased to ₹1,233

Docon Technologies Private Limited entered into a share purchase agreement to acquire 66.11% stake in Thyrocare Technologies Limited (BSE:539871) from a group of shareholders for INR 45.5 billion.

Pharmeasy Looks to Acquire a Stake in Thyrocare

Investor sentiment improved over the past week